Literature DB >> 1374737

HCV and HBV infection among multitransfused thalassemics from eastern Sicily.

B Cacopardo1, R Russo, F Fatuzzo, S Cosentino, T Lombardo, R La Rosa, B M Celesia, L Nigro, V Frontini, A Nunnari.   

Abstract

Serum specimens from 152 Sicilian multitransfused thalassemic subjects were tested for antibodies to hepatitis C virus (anti- HCV) and for HBV markers by enzyme linked immunoassay and with reference to anti-HCV, confirmed by recombinant immunoblot assay. A high rate (47%) of subjects was anti-HCV positive. HBsAg was found in 8% of patients and 55% had anti-HBs or anti-HBc antibodies or both. Contrary to HBV infection, anti-HCV seropositivity was related to the number of transfused units. The highest anti-HCV prevalence was observed between 16 and 20 years; 100% of persons older than 50 years had at least one marker of HBV infection. In conclusion, HCV and HBV are widespread among multitransfused thalassemic. Probably in our area, particularly during the pre-HBsAg screening era, several multitransfused patients were infected by HBV more readily than by HCV.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1374737     DOI: 10.1007/bf01711069

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  16 in total

1.  Transfusion-associated hepatitis not due to viral hepatitis type A or B.

Authors:  S M Feinstone; A Z Kapikian; R H Purcell; H J Alter; P V Holland
Journal:  N Engl J Med       Date:  1975-04-10       Impact factor: 91.245

2.  Antibodies to hepatitis C virus in Italian blood donors.

Authors:  G Sirchia; A Bellobuono; A Giovanetti; M Marconi
Journal:  Lancet       Date:  1989-09-30       Impact factor: 79.321

3.  A multicenter, prospective study of posttransfusion hepatitis in Milan.

Authors:  M Colombo; S Oldani; M F Donato; M Borzio; R Santese; L Roffi; P Viganó; A Cargnel
Journal:  Hepatology       Date:  1987 Jul-Aug       Impact factor: 17.425

4.  Transfusion-associated non-A, non-B hepatitis: an assessment of the causative agent and its clinical impact.

Authors:  H J Alter; A M Prince
Journal:  Transfus Med Rev       Date:  1988-12

5.  Prospective study of posttransfusion hepatitis in cardiac surgery patients receiving only blood or also blood products.

Authors:  F Tremolada; F Chiappetta; F Noventa; C Valfrè; G Ongaro; G Realdi
Journal:  Vox Sang       Date:  1983       Impact factor: 2.144

6.  Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis.

Authors:  H J Alter; R H Purcell; J W Shih; J C Melpolder; M Houghton; Q L Choo; G Kuo
Journal:  N Engl J Med       Date:  1989-11-30       Impact factor: 91.245

Review 7.  Non-A, non-B hepatitis: evolving epidemiologic and clinical perspective.

Authors:  J L Dienstag; H J Alter
Journal:  Semin Liver Dis       Date:  1986-02       Impact factor: 6.115

Review 8.  Transfusion-associated hepatitis C virus (non-A, non-B) infection.

Authors:  H F Polesky; M R Hanson
Journal:  Arch Pathol Lab Med       Date:  1989-03       Impact factor: 5.534

9.  Long-term follow-up of acute and chronic non-A, non-B post-transfusion hepatitis: evidence of progression to liver cirrhosis.

Authors:  G Realdi; A Alberti; M Rugge; A M Rigoli; F Tremolada; L Schivazappa; A Ruol
Journal:  Gut       Date:  1982-04       Impact factor: 23.059

10.  Posttransfusion hepatitis in Spain. A prospective study.

Authors:  J M Hernández; J Piqueras; A Carrera; J Triginer
Journal:  Vox Sang       Date:  1983       Impact factor: 2.144

View more
  1 in total

Review 1.  Hepatitis B, C & D viral markers in multitransfused thalassemic children: long-term complications and present management.

Authors:  V P Choudhry; S K Acharya
Journal:  Indian J Pediatr       Date:  1995 Nov-Dec       Impact factor: 1.967

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.